Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $648.4 million.

  • Celldex Therapeutics' Liabilities and Shareholders Equity fell 2122.75% to $648.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year decrease of 434.8%. This contributed to the annual value of $792.3 million for FY2024, which is 7016.62% up from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Liabilities and Shareholders Equity is $648.4 million, which was down 2122.75% from $692.4 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Liabilities and Shareholders Equity peaked at $868.8 million during Q1 2024, and registered a low of $204.6 million during Q2 2021.
  • In the last 5 years, Celldex Therapeutics' Liabilities and Shareholders Equity had a median value of $444.7 million in 2021 and averaged $508.3 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Liabilities and Shareholders Equity plummeted by 2572.21% in 2023, and later surged by 19372.4% in 2024.
  • Over the past 5 years, Celldex Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $444.7 million in 2021, then dropped by 20.67% to $352.7 million in 2022, then skyrocketed by 32.0% to $465.6 million in 2023, then surged by 70.17% to $792.3 million in 2024, then dropped by 18.16% to $648.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $648.4 million for Q3 2025, versus $692.4 million for Q2 2025 and $739.5 million for Q1 2025.